# A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

> **NCT04898634** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 216 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** JNJ-78278343

## Key facts

- **NCT ID:** NCT04898634
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-13
- **Primary completion:** 2027-02-10
- **Final completion:** 2027-02-10
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04898634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04898634, "A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT04898634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*